# Biochemistry and Pharmacology of the Macular Carotenoids

> **NIH NIH R01** · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2022 · $383,750

## Abstract

Project Summary/Abstract
The macular pigment carotenoids, lutein, zeaxanthin, and lutein’s metabolite meso-zeaxanthin are
uniquely concentrated in the primate foveal region to form the yellow pigment of the macula lutea
where they can enhance visual function and protect against the light-induced oxidative damage that has
been associated with age-related macular degeneration (AMD) and other disorders of the retina. Diets
and supplements enriched in lutein and zeaxanthin are among the most widely prescribed interventions
for patients concerned about future visual loss from AMD, and these xanthophyll carotenoids have
become standard-of-care for individuals with large drusen or advanced AMD in one eye based on
AREDS2 results; however, it is common in the United States for patients and clinicians to integrate
nutritional interventions into clinical practice beyond indications established in large, randomized
clinical trials such as AREDS2, and carotenoids are no exception. For example, lutein has been
incorporated into prenatal supplements and infant formulas without any clinical trials at all, based only
on the hope that it might promote health and development of the child’s visual system, and nondietary
carotenoids such as meso-zeaxanthin are now being promoted as “next generation AREDS
supplements”, again without adequate clinical or basic science studies. The Bernstein laboratory is
dedicated to provide mechanistic insights into the biochemistry, physiology, and pharmacology of the
macular carotenoids to optimize rational, safe interventions against blinding diseases throughout the
lifespan. The key organizing concept that drives the laboratory’s research is that the specific deposition
and protective functions of the three macular carotenoids in the human foveal region are mediated by
complex, regulated interplay of binding proteins, transporters, and metabolic enzymes. The research
group examines this premise using an integrated approach that includes biochemical studies on the
enzymology and protein biochemistry of carotenoid transport and metabolism, animal models for
carotenoid function in the eye in health and disease using transgenic “macular pigment mice”
genetically engineered to have enhanced carotenoid uptake into the retina relative to wild-type mice,
and advanced imaging techniques with particular emphasis on resonance Raman imaging to localize the
macular carotenoids at unprecedented spectral and spatial resolution. The results of these studies will
advance mechanistic knowledge of their physiological functions at a molecular level, which will enable
basic studies that account for their roles in retinal neuroprotection, as well as clinical studies that will
lead to rational, scientifically supported decisions about treatments to prevent visual loss throughout a
person’s lifetime.

## Key facts

- **NIH application ID:** 10519862
- **Project number:** 2R01EY011600-23
- **Recipient organization:** UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- **Principal Investigator:** PAUL STEVEN BERNSTEIN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $383,750
- **Award type:** 2
- **Project period:** 1997-08-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10519862

## Citation

> US National Institutes of Health, RePORTER application 10519862, Biochemistry and Pharmacology of the Macular Carotenoids (2R01EY011600-23). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10519862. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*